---
title: "HUIYU PHARMACEUTICAL: Injectable Parecoxib Sodium and Injectable Pemetrexed Disodium have obtained overseas listing approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252806530.md"
description: "HUIYU PHARMACEUTICAL announced that its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have obtained marketing authorizations in the Netherlands and Saudi Arabia, respectively, for injectable Parecoxib Sodium and injectable Pemetrexed Disodium. This authorization will enrich the company's international product pipeline, enhance brand image, and promote the expansion of international business, laying the foundation for sustainable development"
datetime: "2025-08-13T07:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252806530.md)
  - [en](https://longbridge.com/en/news/252806530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252806530.md)
generator: "portal-rs"
---

# HUIYU PHARMACEUTICAL: Injectable Parecoxib Sodium and Injectable Pemetrexed Disodium have obtained overseas listing approval

According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL (688553.SH) announced that its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have recently received marketing approvals for their products, injectable Parecoxib Sodium and injectable Pemetrexed Disodium, from the Dutch National Institute for Public Health and the Environment and the Saudi Arabian Health Products Regulatory Authority, respectively.

The marketing approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium obtained in the Netherlands and Saudi Arabia are beneficial for the company to enrich its product pipeline in the international market, enhance its brand image, and continuously expand the breadth and depth of its international business, further solidifying the foundation for sustainable development in the international market

### Related Stocks

- [688553.CN](https://longbridge.com/en/quote/688553.CN.md)

## Related News & Research

- [FDA Approves Tablet Form of Zanubrutinib for All Approved Indications](https://longbridge.com/en/news/298434766.md)
- [Foton to showcase battery-electric and hydrogen trucks at IAA Transportation](https://longbridge.com/en/news/298459862.md)
- [C'est parti ! FOTON présente sa gamme complète de produits au salon IAA de Hanovre](https://longbridge.com/en/news/298433893.md)
- [Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign](https://longbridge.com/en/news/298484470.md)
- [05:48 ETIAA Will Kick‑off in Hannover -- Unveiling FOTON's Systematic Global Expansion Blueprint](https://longbridge.com/en/news/298197687.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**